Cediranib Maleate With or Without Dasatinib in Patients With HRPC-Resistant to Treatment With Docetaxel
Status:
Completed
Trial end date:
2014-02-01
Target enrollment:
Participant gender:
Summary
This randomized phase II trial is studying the side effects and how well giving cediranib
maleate together with or without dasatinib works in treating patients with hormone-resistant
prostate cancer resistant to treatment with docetaxel. Cediranib maleate and dasatinib may
stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by
blocking blood flow to the tumor. It is not yet known whether giving cediranib maleate
together with dasatinib or alone is an effective treatment for prostate cancer.